Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
A Phase Ib Study of Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Sponsor: Sanofi
Terminated
Low accrual
Listed as NCT04912427, this PHASE1 trial focuses on Multiple Myeloma and remains terminated or withdrawn. Sponsored by Sanofi, it has been updated 12 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Apr 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Sep 2022 — Apr 2023 [monthly]
Recruiting PHASE1
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .